share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/19 06:04

牛牛AI助理已提取核心訊息

Adial Pharmaceuticals entered into a Purchase Agreement with Alumni Capital LP on December 13, 2024, allowing the company to sell up to $5M of newly issued common stock, with an option to increase to $10M. The purchase price per share will be 97% of the lowest daily volume-weighted average price over a three-day trading period, with a minimum price of $0.55 per share.The agreement runs until December 31, 2026, with Adial maintaining full control over the timing and amount of sales. The company is limited to issuing 1,280,515 shares (19.99% of outstanding shares) unless stockholder approval is obtained. As consideration, Adial issued 68,807 commitment shares to Alumni Capital.Proceeds from any sales will be used for strategic opportunities, staff expansion, working capital, and general corporate purposes. The agreement replaces a previous arrangement with Alumni Capital dated May 31, 2023, which was terminated effective December 13, 2024.
Adial Pharmaceuticals entered into a Purchase Agreement with Alumni Capital LP on December 13, 2024, allowing the company to sell up to $5M of newly issued common stock, with an option to increase to $10M. The purchase price per share will be 97% of the lowest daily volume-weighted average price over a three-day trading period, with a minimum price of $0.55 per share.The agreement runs until December 31, 2026, with Adial maintaining full control over the timing and amount of sales. The company is limited to issuing 1,280,515 shares (19.99% of outstanding shares) unless stockholder approval is obtained. As consideration, Adial issued 68,807 commitment shares to Alumni Capital.Proceeds from any sales will be used for strategic opportunities, staff expansion, working capital, and general corporate purposes. The agreement replaces a previous arrangement with Alumni Capital dated May 31, 2023, which was terminated effective December 13, 2024.
Adial Pharmaceuticals於2024年12月13日與Alumni Capital LP簽署了購買協議,允許公司出售高達500萬美元的新發行普通股,並有選擇權增加至1000萬美元。每股購買價格爲三天交易期內最低日成交量加權平均價格的97%,每股最低價格爲0.55美元。該協議有效期至2026年12月31日,Adial對銷售的時間和數量保持完全控制。除非獲得股東批准,公司限於發行1,280,515股(佔流通股的19.99%)。作爲對價,Adial向Alumni Capital發行了68,807股承諾股份。任何銷售的收益將用於戰略機會、員工擴展、營運資金和一般企業目的。該協議取代了之前與Alumni Capital於2023年5月31日簽訂的協議,該協議於2024年12月13日終止。
Adial Pharmaceuticals於2024年12月13日與Alumni Capital LP簽署了購買協議,允許公司出售高達500萬美元的新發行普通股,並有選擇權增加至1000萬美元。每股購買價格爲三天交易期內最低日成交量加權平均價格的97%,每股最低價格爲0.55美元。該協議有效期至2026年12月31日,Adial對銷售的時間和數量保持完全控制。除非獲得股東批准,公司限於發行1,280,515股(佔流通股的19.99%)。作爲對價,Adial向Alumni Capital發行了68,807股承諾股份。任何銷售的收益將用於戰略機會、員工擴展、營運資金和一般企業目的。該協議取代了之前與Alumni Capital於2023年5月31日簽訂的協議,該協議於2024年12月13日終止。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。